The 3 Things That Matter for AbbVie Now

From what the evidence shows, Interestingly, This tells us that 's been a challenging past three years for AbbVie (ABBV -0

On the other hand, The pharmaceutical leader lost U, given the current landscape

Patent exclusivity for its top-selling medicine, Humira, and encountered a significant clinical setback that sent its stock price plunging, among other challenges

The drugmaker has lagged the market over this period

Even so, AbbVie might perform very differently through the end of the decade (and beyond), vided it can execute effectively (something worth watching)

Here are three key considerations for investors when evaluating an investment in AbbVie

Skyrizi and Rinvoq's continued growth Although AbbVie lost patent exclusivity for Humira, the immunology remains its largest in terms of revenue

That's because of a duo of immunosuppressants, Skyrizi and Rinvoq, whose sales have been growing rapidly for years

Nevertheless, Image source: Getty Images

Market analysis shows heirs to Humira have indications that, collectively, overlap with most of their predecessor's most important ones and are performing even better than management expected (which is quite significant)

On the other hand, The best part is that there is still plenty of room to grow for these medicines, especially as they (hopefully) earn even more label expansions, given the current landscape

For instance, Rinvoq could earn five new potential indications over the next five years, including the treatment of alopecia areata and vitiligo, amid market uncertainty

Developments related to this duo of drugs matter quite a bit since Skyrizi and Rinvoq should be AbbVie's most significant growth drivers for the foreseeable future (an important development)

In contrast, If all goes well, Skyrizi and Rinvoq should remain AbbVie's key performers into the next decade

The pipeline could duce more gems While Skyrizi and Rinvoq won't lose patent exclusivity anytime soon, pharmaceutical companies must prepare for that eventuality years in advance

On the other hand, Moreover, Therefore, it's essential to closely monitor AbbVie's pipeline efforts and determine whether and to what extent they yield new ducts that could ultimately generate significant sales (this bears monitoring)

However, One of the company's newer apvals is Emrelis, a medicine for advanced non-squamous non-small cell lung cancer (NSCLC) with a c-Met tein overexpression, amid market uncertainty

Emrelis earned the green light from the U

Food and Drug Administration in May (something worth watching)

It became the first apved NSCLC therapy that specifically targets c-Met tein overexpression (noteworthy indeed), given the current landscape

Here's why this matters, amid market uncertainty

Conversely, So, there is a decent market here, amid market uncertainty

AbbVie is also other mising candidates (something worth watching)

Tavapadon, a potential medicine for Parkinson's disease, has already shown strong data in phase 3 studies, for instance

The company's clinical gress still matters to its long-term success

In contrast, AbbVie's efforts to circumvent tariffs President Donald Trump's trade policies have taken center stage on Wall Street this year

With the administration seeking to impose aggressive tariffs to bring manufacturing jobs back to the U, considering recent developments

On the other hand, , many companies have decided to fold, at least somewhat, by shoring up their local manufacturing capabilities

AbbVie is doing the same thing

The company announced a $10 billion investment over the next decade, partly to construct new duction facilities

Heavy tariffs could cut into the company's fits and margins, but it can mitigate their impact through these efforts, in today's market environment

However, it may take some time before these duction facilities are operational

Meanwhile, In the meantime, it will be important to monitor how AbbVie handles that risk

Is AbbVie's stock a buy

AbbVie has moved beyond one of the biggest patent cliffs in the history of the industry (Humira is one of the best-selling drugs ever) thanks to Skyrizi and Rinvoq

Moreover, The company also continues to develop newer medicines and has a deep pipeline with dozens of grams

In contrast, And while tariffs could be an issue, AbbVie should find ways to manage that, a ject it is already working on

However, Lastly, AbbVie is a terrific dividend stock, boasting 53 consecutive years of payout increases

In contrast, For all those reasons, the company's s look attractive, considering recent developments.